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Article / Clinical Case Report
ABSTRACT
Inflammatory bowel disease (IBD) has been associated with the development of both gastrointestinal and extraintestinal 
malignancy. The role of therapy in the development of malignancy in IBD has been controversial. We present the case 
of a 40-year-old female patient with long-standing mild IBD, who developed an undifferentiated pleomorphic sarcoma 
of the inguinal region and provide a brief review of the relevant literature. While our case likely represents a coincidence 
of two unrelated pathological entities, clinicians should keep in mind the possibility of soft tissue sarcomas in patients 
chronically treated with anti-inflammatory agents. 
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INTRODUCTION
Undifferentiated pleomorphic sarcoma (UPS), 
formerly known as malignant fibrous histiocytoma, is 
a genome unstable soft tissue or bone neoplasm that 
can arise from any part of the body. While most cases 
represent a dedifferentiated form of leiomyosarcoma 
and liposarcoma, in a minority of cases no evidence of 
differentiation can be found.1 Most undifferentiated 
high-grade sarcomas occur in patients over age 40, 
and have a less aggressive clinical course compared 
with more differentiated tumors.2 While the majority of 
sarcomas seem to arise without a predisposing factor, 
irradiation, immunosuppression, exposure to certain 
chemicals, viral infection and germline mutations have 
been implicated as etiologic factors in some types, with 
radiotherapy specifically being linked to UPS.1
Inflammatory bowel disease (IBD) has been 
associated with an increased risk of development of 
gastrointestinal as well as extraintestinal malignancies.3,4 
The gastrointestinal cancers include colon and small 
bowel adenocarcinoma, cholangiocarcinoma and 
anal squamous cell carcinoma. The pathogenesis of 
these cancers is linked to the prolonged inflammation 
characteristic of IBD. Evidence supports an increased risk 
of extraintestinal malignancies including lymphomas,5 
non-melanoma skin cancer,6 urothelial cancer7 and 
HPV (human papilloma virus)-related cervical cancer. 
The excess risk of extraintestinal malignancies has been 
attributed to IBD treatment modalities, namely systemic 
immunosuppression using thiopurines, corticosteroids, 
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methotrexate and anti-tumor necrosis factor (anti-TNF) 
antibodies.5
Patients with IBD might also have an increased 
risk of developing thyroid,8 breast,9 and oral cancer10 
although the potential underlying mechanisms remain 
unknown. Several case reports11-13 of sarcomas arising 
in the context of immunosuppressant therapy for IBD 
have raised the question whether an increased risk 
for the development of soft tissue tumors exists in 
IBD patients.
CASE REPORT
A 40-year old woman was admitted to our hospital 
for evaluation of a rapidly growing, painless inguinal 
mass of four-month duration. She was a smoker 
with long-standing Crohn’s disease diagnosed at age 
20, with mild remitting gastrointestinal symptoms, 
responsive to therapy with topical and systemic 
5-aminosalicylic acid. She has been in remission for 
5 years at the time of the present complaint. She also 
developed a concomitant autoimmune thyroiditis.
The physical examination showed a palpable, 
hard, mobile nodule in the left inguinal region. 
On ultrasound examination, a hypoechoic formation 
measuring 30 mm in greatest diameter was found. 
The tumor was located in the soft tissues distal to 
the lymphatic inguinal region. A lymph node lesion 
was suspected, and fine needle aspiration cytology 
showed poorly differentiated tumor cells resembling 
melanoma (Figure 1). However, a detailed history 
and dermatologic exam revealed no evidence of skin 
lesions.
An addit ional  exc is ion b iopsy showed a 
well-circumscribed tumor with a fleshy cut surface 
with foci of hemorrhage and necrosis. On microscopic 
examination, the tumor consisted of anaplastic and 
pleomorphic cells, with atypical mitoses and invasion of 
surrounding adipose tissue. Immunohistochemically the 
neoplastic cells showed strong positivity for vimentin, 
while CD 34, smooth muscle markers (smooth muscle 
actin, h-caldesmon, myogenin), melanoma markers 
(HMB 45, melan A, S 100), vascular markers (CD 31, 
CD 34), CD 68, MDM 2 and cytokeratin were negative 
(Figure 2).
Figure 1. Photomicrography of the fine needle aspiration showing poorly differentiated tumor cells.
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By the microscopic and immunohistochemical 
analysis, a diagnosis of exclusion of high-grade, 
undifferentiated pleomorphic sarcoma was made. 
Sample margins were positive, and re-excision was 
performed, with histology showing foci of deep 
residual tumor.
Her treatment included local radiotherapy, and at 
10 months of follow up, she is disease free.
DISCUSSION
IBD therapies have been implicated in the 
pathogenesis of malignancy. Anti-TNF antibodies 
and thiopurines have been associated with the 
development of lymphoproliferative disorders,14 
while thiopurines alone have been shown to increase 
the risk of non-melanoma skin cancer.6 Prolonged 
immunosuppression might ostensibly hinder immune 
system control of cancerous cells, thereby accelerating 
tumor growth. Anti-TNF antibodies have been shown 
to promote neoplastic cell survival via the nuclear 
factor kappa B (NF-kB) pathway, while thiopurines 
are implicated in the pathogenesis of lymphomas 
related to a reactivation of latent Epstein-Barr virus 
(EBV) infection.14 Case reports of Kaposi sarcoma in 
immunosuppressed IBD patients have been published, 
with a reactivation of underlying human herpes virus 
8 (HHV-8) infection postulated as a possible cause.15-17
Genome-wide association studies have not found 
a possible genetic link between IBD and predisposition 
to malignancy.18 A link between inflammation and 
sarcoma development, however, is supported by 
Figure 2. Photomicrography of the biopsy specimen showing in A – anaplasia and atypical mitotic figures (H&E, 
200x); in B – diffuse immunohistochemical positivity for vimentin (200x), and negative for desmin in C (200x) and 
CD34 in D (200x).
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a growing body of evidence,19 including studies of 
inflammatory malignant fibrous histiocytoma, in which 
altered hypoxia-induced factor 1 (HIF-1) and NF-kB 
signaling might play a role.19
In a recent retrospective cohort study, a 10-fold 
increase in the risk of oral cancer was found among 
IBD patients. Out of the 11 cases, 3 were reported as 
sarcoma.10 No association with immunosuppressive 
therapy was reported. In our case, no prolonged 
systemic immunosuppressive therapy was needed 
to control IBD symptoms, and the patient was 
symptom-free for 5 years before her sarcoma diagnosis.
Our case is the first published concurrence of 
undifferentiated pleomorphic sarcoma and IBD, and 
although it likely represents a coincidence of two 
unrelated pathological entities, clinicians should be 
aware of the possibility of soft tissue malignancy in IBD 
patients, especially in the setting of poorly controlled 
disease requiring prolonged immunosuppression.
The possible association of mesenchymal 
malignancies and IBD is poorly understood, and 
further, more detailed studies are needed to shed light 
on this question.
This case report is in accordance with the Ethics 
Committee recommendations of “Sestre milosrdnice” 
University Hospital Centre.
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